Clinical Trial: NCT01597388
AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer
Status:
COMPLETEDPhase:
Phase 1| Lead Sponsor: | AstraZeneca |
| Information Provided By: | AstraZeneca |
| Last Update Posted: | 2026-02-24 |
Study Overview
Brief Summary
The purpose of this study is to assess safety and tolerability of AZD2014 when given in combination with Fulvestrant
Official Title
A Phase I, Open-label, Multicentre, Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD2014 Administered Orally in Combination With Intramuscular (IM) Fulvestrant to Patients With Estrogen Receptor Positive (ER+) Advanced, Metastatic Breast Cancer
Conditions
Advanced Metastatic Breast Cancer
Intervention / Treatment
- Drug: AZD2014
- Drug: Fulvestrant
Other Study ID Numbers
- D2270C00005
- BRE-196
- 264477
Start Date (Actual)
2012-05-08
Primary Completion Date (Actual)
2016-08-04
Study Completion Date (Actual)
2026-01-13
Enrollment (Actual)
99
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | AstraZeneca |
| Information Provided By: | AstraZeneca |
| Last Update Posted: | 2026-02-24 |
Study Overview
Brief Summary
The purpose of this study is to assess safety and tolerability of AZD2014 when given in combination with Fulvestrant
Official Title
A Phase I, Open-label, Multicentre, Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD2014 Administered Orally in Combination With Intramuscular (IM) Fulvestrant to Patients With Estrogen Receptor Positive (ER+) Advanced, Metastatic Breast Cancer
Conditions
Advanced Metastatic Breast Cancer
Intervention / Treatment
- Drug: AZD2014
- Drug: Fulvestrant
Other Study ID Numbers
- D2270C00005
- BRE-196
- 264477
Start Date (Actual)
2012-05-08
Primary Completion Date (Actual)
2016-08-04
Study Completion Date (Actual)
2026-01-13
Enrollment (Actual)
99
Study Type
Interventional
Phase
Phase 1